Presence of a novel variant NDM-10, of the New Delhi metallo-beta-lactamase in a Klebsiella pneumoniae isolate
Dear Editor, Emerging carbapenem resistance in Enterobacteriaceae represents a significant threat to public health because it reduces the effectiveness of antimicrobial treatment. Broncheo-alveolar lavage fluid from a 65 years old patient grew Gram-negative, non-motile bacilli in pure culture. The organism was identified as Klebsiella pneumoniae (Labelled as KPN 78) by Vitek-2 system using VITEK-GNI cards (bioMérieux, Marcy l'Etoile, France). Antibiotic sensitivity test was performed by standard Kirby-Bauer disc diffusion technique as per the guidelines of the Clinical Laboratory Standards Institute (CLSI) [1] with commercially available discs (Hi-Media, Mumbai, India) on Mueller Hinton agar plates. The isolate was resistant to all beta-lactams and their minimum inhibitory concentrations (MICs) of are shown in Table 1 , whereas MICs of colistin and tigecycline are 0.75 μg/ml and 1 μg/ml respectively as determined by VITEK-2 and E-test as per CLSI breakpoints. Modified Hodge's Test and MBL (IP/IPI) E-test (bioMérieux, Marcy l'Etoile, France) for MBL production was positive. Bacterial DNA was extracted using the spin column method (QIAGEN; GmbH, Hilden, Germany) as per manufacturer's instructions. Polymerase chain reaction (PCR)-based analysis for beta-lactamase genes (bla CTXM, bla OXA, bla SHV and bla TEM ), Ambler class B MBLs (bla IMP , bla VIM , bla SPM , bla GIM , bla SIM, bla NDM-1), Ambler classD (bla OXA-23 , bla OXA-24 , bla OXA48 ), serine carbapenemases (bla KPC, bla GES and bla NMC ) and for 16S rRNA methylase gene was carried out in a Gene Amp 9700 PCR System (Applied Biosystems, Singapore). PCR primers used as described earlier [2] were procured from Sigma-Aldrich, India. The isolates were positive for bla NDM and harbored 16S rRNA armA methylase gene, encoding high-level resistance to all aminoglycosides. The amplicons were purified using QIAquick PCR purification kit (QIAGEN; GmbH, Hilden, Germany) and sequenced with the ABI 3730XL capillary sequencer (Applied Biosystems, Foster City, CA, USA). The chromatogram was analysed, consensus sequences were aligned using BioEdit software and showed five mutations corresponding . In addition to bla NDM-10 , isolate was positive for extended-spectrum beta-lactamase genes and sequencing showed the presence of bla CTX-M-15 , bla TEM-1 and bla SHV-28. The point mutations at position 94 (C→A), 107 (G→A), 205 (G→A), 220 (G→A) and 598 (G→C) responsible for the amino acid substitutions were confirmed by reamplification and sequencing of gene from fresh DNA preparation. The NDM-10 gene was localised on a plasmid of ca. 130 kb in size as demonstrated by Southern hybridization with a bla NDM -specific probe.
Liqid broth mating-out assays was carried out at 37°C using K. pneumoniae isolate (Parental strain) as donos and an azide-resistant Escherichia coli J53 as the recipient strain in 1:10 ratio. Selection of the transconjugants was based on growth on MacConkey agar supplemented with sodium azide (100 μg/ml), cefoxitin (10 μg/ml) and ceftazidime (30 μg/ml). Mating-out assays followed by PCR of transconjugant [ Table 1 ] showed bla NDM-10 gene on a 130-kb plasmid and bla CTX-M-15 , bla TEM-1 and bla SHV-28 on 70 kb plasmid. Using the PCR-based replicon typing method as described previously. [3] Bla NDM-10 gene was located on a plasmid typed as IncFII-type (Amplicon size of 270 bp). Plasmid carrying bla CTX-M-15 , bla TEM-1 and bla SHV-28 showed association with multiple replicons (IncFIB and IncFIA). A ca. 130-kb plasmid was successfully transferred to E. coli DH10B by electroporation and transformant displayed similar beta-lactam resistance expression pattern as that of NDM-10 [ Table 1 ]. Here, we report a novel NDM-10 in K. pneumoniae KPN-78 isolate and due to these mutations, isolate is showing higher MICs values against beta-lactam antibiotics as compared to NDM-1 [ Table 1 ]. Due to higher MICs the patient is clinically resistant to all beta-lactam group of antibiotics, fluoroquinolones, aminoglycosides, beta-lactam and beta-lactam inhibitor combinations and beta-lactam and an aminiglycoside combination. Colistin is the mainstay of therapy.
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Evaluation of the antibiotic resistance of Pseudomonas aeruginosa isolates according to the changing guidelines
Sir,
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen that commonly found in nature. [1] Resistance to antibiotics and disinfectants is a problem in healthcare settings [2] some regulations are made in susceptibility testing and interpretation of results. Clinical and Laboratory Standards Institute (CLSI) guideline changed the minimum inhibitory concentrations (MICs) of piperacillin, piperacillin tazobactam, imipenem and meropenem which are used in the treatment of Pseudomonas infections, in 2012. [3] The aim of this study was; evaluating MIC values of P. aeruginosa isolates which were isolated from clinical specimens according to the CLSI 2011. [4] CLSI 2012 [3] and European Committee on Antimicrobial Susceptibility Testing (EUCAST) [5] guidelines, to reveal differences in susceptibility rates and to contribute to the debate on guide exchange.
A total of 3632 strains for imipenem, 3706 strains for meropenem, 3479 strains for piperacillin and 4760 strains for piperacillin-tazobactam were enrolled in this study. Identification of the strains and MIC values have been studied in Phoenix (BD Diagnostic, ABD) and Vitek2 (Biomerieux, France) automated systems.
When compared CLSI 2011 and 2012 criteria, it was observed that the rate of imipenem-susceptible strains were decreased from 58% to 54 5% and the rate of intermediate strains were increased from 4% to 7 5%. Furthermore, similar changes have been seen for meropenem and 4% decrease was observed for susceptible strains. However, 10% decrease was determined for the rate of susceptible strains for piperacillin and piperacillin-tazobactam [ Table 1 ]. According to EUCAST criteria, while MIC values for imipenem is similar to CLSI 2011, susceptible strain rate same with CLSI 2011 and it was determined to be higher according to CLSI 2012. MIC values in EUCAST for piperacillin and piperacillin-tazobactam is lower and the susceptibility MIC value is same with CLSI 2012.
